Dicerna Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Watertown MA United States (2007)
Status: Acquired by Novo Nordisk (2021)

Organization Overview

First Clinical Trial
2014
NCT02110563
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dicerna Pharmaceuticals | Dicerna Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

nedosiran (rivfloza) (6 trials)

Drugs in Phase 2 Trials (2)

dcr-a1at (3 trials)

dcr-myc (2 trials)

Drugs in Phase 1 Trials (3)

dcr-aud (1 trial)

dcr-hbvs (1 trial)

dcr-ph1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Genetic Diseases, Inborn (Phase 3)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Hyperoxaluria, Primary (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 2)

Liver Diseases (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Neuroendocrine Tumors (Phase 1)

Urologic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 6